LLY

710.61

+0.3%↑

JNJ

179.04

+0.08%↑

ABBV

210.25

+0.41%↑

UNH

306.92

+1.28%↑

AZN

80.93

+0.65%↑

LLY

710.61

+0.3%↑

JNJ

179.04

+0.08%↑

ABBV

210.25

+0.41%↑

UNH

306.92

+1.28%↑

AZN

80.93

+0.65%↑

LLY

710.61

+0.3%↑

JNJ

179.04

+0.08%↑

ABBV

210.25

+0.41%↑

UNH

306.92

+1.28%↑

AZN

80.93

+0.65%↑

LLY

710.61

+0.3%↑

JNJ

179.04

+0.08%↑

ABBV

210.25

+0.41%↑

UNH

306.92

+1.28%↑

AZN

80.93

+0.65%↑

LLY

710.61

+0.3%↑

JNJ

179.04

+0.08%↑

ABBV

210.25

+0.41%↑

UNH

306.92

+1.28%↑

AZN

80.93

+0.65%↑

Home・Aandelen Lijst・Altimmune Inc

Altimmune Inc

Gesloten

3.53 0.28

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

3.5

Max

3.65

Belangrijke statistieken
By Trading Economics
Inkomsten	-2.6M -22M
Verkoop	5K
Winstmarge	-442,920
Werknemers	59
EBITDA	-2.7M -23M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+484.42% upside

Dividenden
By Dow Jones
Volgende Winsten	11 nov 2025

Marktinformatie
By TradingEconomics
Marktkapitalisatie	40M 314M
Vorige openingsprijs	3.25
Vorige sluitingsprijs	3.53

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

5.365 / 6.0486 Steun & Weerstand

Altimmune Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

22 aug 2025, 23:09 UTC

Acquisities, Fusies, Overnames

Trump Says U.S. Will Take Nearly 10% Equity Stake in Intel -- 4th Update

22 aug 2025, 22:02 UTC

Acquisities, Fusies, Overnames

Agreement Could Also Lead to Deeper Collaboration Between CSX, BNSF

22 aug 2025, 22:02 UTC

Acquisities, Fusies, Overnames

Some Analysts Say Agreement Suggests Lack of Confidence in Merger

22 aug 2025, 22:02 UTC

Acquisities, Fusies, Overnames

CSX, BNSF Intermodal Pact Draws Competing Views on Merger Possibility

22 aug 2025, 22:02 UTC

Acquisities, Fusies, Overnames

CSX, BNSF Pact Sparks Debate on Whether Another Rail Merger Is Approaching -- Analysis

22 aug 2025, 22:02 UTC

Acquisities, Fusies, Overnames

Pact Could Show Regulators That Transcontinental Service Can Come Without Merger

22 aug 2025, 21:23 UTC

Marktinformatie

Moody's Lowers Outlook on Austria to Negative From Stable -- Market Talk

22 aug 2025, 21:18 UTC

Marktinformatie

US Economic Growth Seen Slowing This Year -- Market Talk

22 aug 2025, 21:18 UTC

Acquisities, Fusies, Overnames

U.S. Takes 10% Stake in Intel -- Barrons.com

22 aug 2025, 21:03 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

22 aug 2025, 21:03 UTC

Marktinformatie

Mexican Stocks Close At Record High -- Market Talk

22 aug 2025, 20:58 UTC

Marktinformatie

US General Government Deficit Expected to Rise in 2026, 2027 -- Market Talk

22 aug 2025, 20:57 UTC

Acquisities, Fusies, Overnames

Intel: Government's Investment in Intel Will Be a Passive Ownership, With No Bd Representation or Other Governance or Info Rights >INTC

22 aug 2025, 20:57 UTC

Acquisities, Fusies, Overnames

Intel: Government Also Agrees to Vote With the Company's Bd of Directors on Matters Requiring Shareholder Approval, With Limited Exceptions >INTC

22 aug 2025, 20:57 UTC

Acquisities, Fusies, Overnames

Intel: Government Equity Stake Will Be Funded by Remaining $5.7B in Grants Previously Awarded, But Not Yet Paid, Under U.S. CHIPS and Science Act and $3.2B Awarded as Part of Secure Enclave Program >INTC

22 aug 2025, 20:57 UTC

Acquisities, Fusies, Overnames

Intel: Government Agrees to Purchase 433.3M Primary Shrs of Intel Common Stk at a Price of $20.47 per Shr, Equivalent to a 9.9% Stake in Co >INTC

22 aug 2025, 20:57 UTC

Acquisities, Fusies, Overnames

Intel: U.S. Government to Make $8.9B Investment in Intel Common Stk as Co Builds Upon Its More Than $100B Expansion of Resilient Semiconductor Supply Chain >INTC

22 aug 2025, 20:57 UTC

Acquisities, Fusies, Overnames

Intel: Intel and Trump Admin Reach Historic Agreement to Accelerate Amer Technology and Manufacturing Leadership

22 aug 2025, 20:56 UTC

Winsten

These Stocks Moved the Most Today: Nvidia, Builders FirstSource, Zoom, Intuit, Workday, BJ's, Ubiquiti, and More -- Barrons.com

22 aug 2025, 20:55 UTC

Winsten

These Stocks Are Moving the Most Today: Nvidia, Builders FirstSource, Zoom, Intuit, Workday, BJ's, Ubiquiti, and More -- Barrons.com

22 aug 2025, 20:50 UTC

Marktinformatie

Winsten

Tech, Media & Telecom Roundup: Market Talk

22 aug 2025, 20:50 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Basic Materials Roundup: Market Talk

22 aug 2025, 20:41 UTC

Acquisities, Fusies, Overnames

U.S. Has 10% Stake in Intel, Lutnick Says -- Barrons.com

22 aug 2025, 20:24 UTC

Acquisities, Fusies, Overnames

Trump Says U.S. Will Take Nearly 10% Equity Stake in Intel -- 3rd Update

22 aug 2025, 20:16 UTC

Acquisities, Fusies, Overnames

CSX and Warren Buffett's BNSF Made News. Why Investors Are Disappointed. -- Barrons.com

22 aug 2025, 19:19 UTC

Marktinformatie

Boeing to Restart Talks With Defense Workers' Union Monday -- Market Talk

22 aug 2025, 19:10 UTC

Marktinformatie

Oil Futures Gain as Russia-Ukraine Peace Seems Distant -- Market Talk

22 aug 2025, 19:06 UTC

Marktinformatie

U.S. Natural Gas Extends Losses as Summer Nears an End -- Market Talk

22 aug 2025, 19:03 UTC

Marktinformatie

Lower Borrowing Rates Elusive Even if Fed Cuts -- Market Talk

22 aug 2025, 18:52 UTC

Acquisities, Fusies, Overnames

Trump Says U.S. Will Take Nearly 10% Equity Stake in Intel -- 2nd Update

Peer Vergelijking

Prijswijziging

Altimmune Inc Prognose

Koersdoel

By TipRanks

484.42% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 20.63 USD 484.42%

Hoogste 28 USD

Laagste 12 USD

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor Altimmune Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

10 ratings

Buy

Hold

Sell

Gebaseerd op 10 analisten die aandelenratings hebben gegeven aan Altimmune Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

5.365 / 6.0486Steun & Weerstand

Recent bullish events outweigh bearish events.

All events are bearish.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Altimmune Inc

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.